2024 POSTER PRESENTATIONS COMING IN APRIL
Check back for an updated list of the titles to be presented in 2024.
Here's a reminder of the 2023 Poster Presentations:
P001: Fast Track Antigen-Specific B- and T-Cell Discovery Using Barcode Enabled Antigen Mapping (BEAM), Presented by Bruce A., 10x Genomics
P002: Out of the Box Tools for Antibody Characterization, Presented by Vera M., 2bind GmbH
P003: TCR Mimetic Antibody Discovery, Characterization, and Optimization Enabled by the AlphaSeq Platform, Presented by Emily E., A-Alpha Bio, Inc.
P004: Cytokine Affinity Tuning Using the AlphaSeq Platform to Generate Targeted Immuno-Oncology Therapeutics, Presented by Jeffrey A., A-Aplha Bio, Inc.
P005: Machine Learning Guided Antibody Optimization of a SARS-CoV-2 Binding Antibody Enabled by AlphaSeq, Presented by Randolph L., A-Aplha Bio, Inc.
P006: Custom-Build Optimal T-Cell Engagers for Diverse Tumor Targets with Differentiated CD3-Binding Antibodies, Presented by Raffi T., AbCellera Biologics, Inc.
P007: Breaking Barriers to Access Intracellular Targets with T-Cell Engagers: Discovery of Diverse, Developable, and Ultra-Specific Antibodies Against a MAGE-A4 pMHC, Presented by Davide T., AbCellera Biologics, Inc.
P008: High Throughput, High Fidelity Data Generation to Enable AI Lead Optimization, Presented by Vincent B., Absci Corporation
P009: Antibody Design Using Generative AI, Presented by Amir S., Absci Corporation
P010: Deep Learning-Based Codon Optimization with Large-Scale Synonymous Variant Datasets Enables Generalized Tunable Protein Expression, Presented by David S., Absci Corporation
P011: Comparing Potential Bispecific Formats of Trastuzumab and a Humanized OKT3, Presented by Michael F., Absolute Antibody
P012: Dual Action Antibodies for Treatment of Progressive Multiple Sclerosis, Presented by Hiep T., Abzyme Therapeutics
P013: Sequential Activation of Multiple Gene Copies Facilitates Adaptation of CHO Cells to Increased Productivity, Presented by Victor JL., ACIB GmbH
P014: SLAM-seq Reveals Early Transcriptomic Response Mechanisms upon Glutamine Deprivation in Chinese Hamster Ovary Cells, Presented by Maja P., ACIB GmbH
P015: Accelerating the Development of Novel Antibody-Drug Conjugates Through Site-Specific Conjugation Methods, Presented by An O., ACROBiosystems
P016: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform, Presented by Garrett R., Adimab LLC
P017: Investigating Thermal Stability of Nucleic Acids and Proteins Using the Agilent Cary 3500 UV-Vis Spectrophotometer, Presented by Ryan B., Agilent Technologies
P018: Site-Specific Incorporation of Non-Canonical Amino Acids by Proprietary Microbial Protein Expression System, Presented by Yumi N., Ajinomoto Co., Inc.
P019: From Peptides and Small Proteins to mAb, Ajinomoto's Proprietary Microbial Platform for Pharmaceutical Protein Production, Presented by Kazuo Y., Ajinomoto Co., Inc.
P020: Development of a Novel Anti-IL-5Ra Antibody with Improved Efficacy and a First-in-Class Bispecific T Cell Engager for Eosinophilic Asthma Therapy, Presented by Jun-Ho K., Ajou University
P021: Improved Intratumoral Penetration of IL12 Immunocytokine Enhances the Antitumor Efficacy, Presented by Seul Gi L., Ajou University
P022: Affinity-Guided Photocrosslinking Methodology for Site-Specific Conjugation of Antibody and Payload, Presented by Jisoo P., Ajou University
P023: Bispecific Antibodies Expand Therapeutic Breadth Across Divergent Filoviruses, Presented by Ariel W., Albert Einstein College of Medicine
P024: ATP128 Vaccine in Combination with Ezabenlimab Promotes Antigen-Specific Immune Responses in Stage IV Colorectal Cancer in KISIMA-01 Phase 1b Trial, Presented by Roberta P., Amal Therapeutics SA
P025: Primary Human Immune Cell Assays for the Evaluation of New Immuno-Oncology Therapies, Presented by Robert B., Antibody Analytics Ltd.
P026: Quantification of the Antigen Density Activation Threshold for Targeted Immunotherapeutics, Presented by Timothy L., Antibody Analytics Ltd.
P027: Capturing the Functional Antibody Repertoire from Multiple B-Cell Subsets Following Antigen Stimulation, Presented by John K., Antibody Solutions
P028: Gastric Cancer Antibody Fragment Drug-Conjugates (FDCs): Applying a Successful Concept to Solid Tumours, Presented by Mahendra D., Antikor Biopharma Ltd.
P029: Assessment of Statistical Significance of Minor Changes in HOS Using Circular Dichroism – A New Approach, Presented by Janel D., Applied Photophysics
P030: Tracking Changes in the Cellular Immune Response During Development of Multiple Myeloma from Premalignant to Malignant Disease, Presented by Suchita J., Ariel University
P031: Development of a High-Throughput Epitope Fingerprinting Method for Complex Membrane Proteins, Presented by Amy H., AstraZeneca
P032: Leap-In Transposases® - A New Paradigm in Cell Line Development, Presented by Oren B., ATUM
P033: Rapid Generation of Potent Antibodies by Autonomous Hypermutation in Yeast, Presented by Alon W., Aureka Biotechnologies
P034: A High Throughput Bispecific Antibody Discovery Pipeline, Presented by Weian Z., Aureka Biotechnologies
P035: Sequencing to Synthesis: Innovative Antibody Discovery Workflow Leveraging Biological Intelligence to Prioritize Leads, Presented by Ilaria D., Azenta Life Sciences
P036: Increasing IL-11 Function Blocking Antibody Binding Strength and Potency Using a Bi-Paratopic Antibody Format, Presented by Philipp E., Bayer AG
P037: An Anti-HER2/Trop-2 Bispecific Antibody-Drug Conjugate with a New DNA Topoisomerase I Inhibitor Exerts Potent and Broad Antitumor Activity in Preclinical Tumor Models, Presented by Helen Z., BiOneCure Therapeutics, Inc.
P038: Rapid and High Throughput Crude IgG Quantification For Ab Discovery and Development Using the Valita®Titer Assay
, Presented by Brian M., Beckman Coulter Life Sciences – ValitaCell
P039: NKp46 Engaging Bicycle NK- TICA™ Drives Tumor Targeted Cytotoxicity, Presented by Sandra U., Bicycletx Ltd.
P040: Using Conjugation Technology to Increase the Efficacy and Specificity of a MYC-Inhibiting Oligonucleotide, Presented by Samantha B., Binghamton University, State University of New York
P041: Design, Evaluation, and Optimization of Immune Stimulating Antibody-Drug Conjugates for Cancer Treatment, Presented by Siteng F., Binghamton University, State University of New York
P042: Pharmacology of Legumain-Cleavable MMAE Containing ADC Linkers, Presented by Meghan G., Binghamton University, State University of New York
P043: Novel Dual-Loaded ADC Elicits Both Cytotoxic and Immune-Modulating Effects in In-Vitro Pancreatic Cancer Model, Presented by Victor O., Binghamton University, State University of New York
P044: An Ultra-High-Throughput Screen for the Evaluation of Peptide HLA-Binder Interaction, Presented by Stefan K., BioCopy GmbH
P045: High Throughput Kinetic Characterization of a WT1 Specific TCR Like Antibody Using Novel pHLA Microarrays, Presented by Johannes W., BioCopy GmbH
P046: PEAKS AB 3.0: Accurate De Novo Sequence Assembly and Glycan Profiling of Antibodies, Presented by Kyle H., Bioinformatics Solutions, Inc.
P047: Biointron: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Shi L., Biointron Biological, Inc.
P048: Development of High Throughput Single-B Cell Antibody Discovery Platform, Presented by Shi L., Biointron Biological, Inc.
P049: Pioneer: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Christian F., Bio-Rad AbD Serotec GmbH
P050: TrailBlazer: A Rapid Modular Antibody Assembly Platform, Presented by Christian F., Bio-Rad AbD Serotec GmbH
P051: Rapid Generation of Bispecific Antibodies for High-Throughput Screening, Presented by Christian H., Bio-Rad AbD Serotec GmbH
P052: Discovery and Development of Anti-CD40 Agonistic Antibody for Cancer Immunotherapy, Presented by Mingjiu C., Biosion, Inc.
P053: Streamlined Process for Automated Plasmid Purification Reduces Labour Time and Increases Titres for AAV Production, Presented by Shadie N., Biotage
P054: Evolution of a Hyperactive TcBuster™ Transposase Enables Highly Efficient Non-Viral Generation of CAR-NK and CAR-T Cells for Combination Cell Therapies, Presented by Neil O., Bio-Techne
P055: Trends in Industrialization of Biotherapeutics: A Survey of Product Characteristics of 89 Antibody-Based Biotherapeutics, Presented by Kyle M., Boehringer Ingelheim
P056: In Silico Prediction and In Vitro Fab Analysis of the Structural Basis of Lecanemab Paratope Binding Site, Presented by Jean-Pierre B., Brigham and Women's Hospital
P057: Tracing the Fate of Therapeutics-Conjugates at Subcellular Level via Imaging Mass Spectrometry, Presented by Christelle G., Brigham and Women's Hospital
P058: Development of Functionalized Microbead-Based Immunoassay by qPCR for the Detection of Amyloid-Beta(1-42) Monomer in Plasma, Presented by Jennifer P., Brown University
P059: CALIXAR’S Toolbox for Native Membrane Targets, Presented by Vincent C., CALIXAR
P060: Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR, Presented by Nico A., Carterra, Inc.
P061: LSAXT: Extending the Applications Space of HT-SPR, Presented by Nico A., Carterra, Inc.
P062: Use of High Throughput SPR to Characterize Antibodies to Common Cancer Biomarkers, Presented by Nico A., Carterra, Inc.
P063: Biophysical Characterization of MR1 (K43A)/ß2M Complex, Presented by Sangeetha S., Cayman Chemical Company
P064: Role of Cancer Associated Glycan in the Regulation of Tumor Microenvironments, Presented by John Y., Chang Gung Memorial Hospital at Linkou
P065: Constrained Peptide Modeling, Conformational Analysis and Property Predictions, Presented by Philippe A., Chemical Computing Group
P066: Developability Assessment and Property Prediction by pH-Dependent Conformational Sampling, Presented by Nels T., Chemical Computing Group
P067: Functional Evaluation of Unique Anti-PDL1 Antibodies Generated Through Single Plasma B Cell Cloning on the Beacon® Platform Versus a Standard Hybridoma Approach, Presented by Mizanur R., ChemPartner USA
P068: Structural Characterization of Hsp40 Protein, Tid1 Using NMR, Presented by Jinhwa J., Chungbuk National University
P069: Development of an Ultra-High Affinity, Trimeric ACE2 Biologic as a Universal COVID Antagonist, Presented by Juliet G., City of Hope
P070: CB307: A Novel T-Cell Costimulatory Humabody VH Therapeutic for PSMA-Positive Tumours, Presented by Colette J., Crescendo Biologics Ltd.
P071: Fast-Tracking Development to Pre-Clinical: High Throughput and High Yield Transient Production in CHO and HEK293 Systems, Presented by Hans L., Curia
P072: A Scalable Single-Use Two-Step Plasmid Purification Process, Presented by Simon A., Cytiva
P073: Detection of Antigen-Specific IgG Isotypes in Crude Plasma by SPR, Presented by Olof K., Cytiva
P074: Investigating Complex Molecular Interactions Using Novel SPR Analysis Approaches, Presented by Olof K., Cytiva
P075: Doubling Process Productivity and Speeding Up Process Development with Mechanistic Modeling for Chromatography, Presented by John S., Cytiva
P076: bioMT Cores: Advancing Research at Dartmouth, Presented by Andreia V., Dartmouth College
P077: Unexpected Antibody-Like Stability and Characteristics of the Targeted Dual Cytokine Fusion Therapeutic, DK210(EGFR), Presented by David B., Deka Biosciences
P078: Development of Anti-CD73 Antibody for Cancer Immunotherapy, Presented by Chen-Jei H., Development Center for Biotechnology
P079: Training the Future of the Bioeconomy: Creating Accessible Research Experiences in Protein Engineering Using the Immune Epitope Database, Presented by Miko M., Digital World Biology
P080: DimAb® Single B Cell Cloning Platform and Its Application on CAR T-Cell Therapy Construct Development, Presented by Donghui M., DIMA Biotechnology Ltd.
P081: Rapid and High Throughput Biosensor Kinetics Screening in Early Antibody Discovery, Presented by Christina P., Distributed Bio, A Charles River Company
P082: Enzymatic DNA Synthesis (EDS) Allows Rapid Access to Synthetic Oligos to Produce Expression Vectors for SARS-CoV-2 Spike Variants, Presented by Raymond D., DNA Script
P083: Rapid, High Yield Eukaryotic Gene Expression Platform to Rival CHO; Faster, Higher Yield, Lower Cost Way to Develop and Manufacture Biologics, Presented by Joseph H., Dyadic International, Inc.
P084: Fully Automated Miniaturized Ultra-High Throughput Screening of Cells and Biomolecules, Presented by Martin M., Efficient Robotics GmbH
P085: Comprehensive and Fit-For-Purpose Solutions to Enable Drug Development for Cytokine Targets, Presented by Venkatesh C., Eurofins DiscoverX
P086: Accelerate Drug Development of GLP-1 and -2 Receptor Analogs with Ready-to-Use Cell-Based Assays, Presented by Debatri C., Eurofins DiscoverX
P087: EVOLVE – A Next-Generation CD2 Costimulation T Cell Engager Platform for Solid Tumors, Presented by Guixian J., EvolveImmune Therapeutics, Inc.
P088: Biophysical Characterization Roadmap for Developability Assessment During Antibody Discovery, Presented by Teresa B., FairJourney Biologics
P089: High Throughput Approaches for Production and Characterization in Antibody Discovery, Presented by Joana M., FairJourney Biologics
P090: Assessment of Sample Quality with Every Measurement, Presented by Ann Marie B., Fida Biosystems ApS
P091: Flow Induced Dispersion Analysis (FIDA) to Measure gRNA-Nuclease Interactions for CRISPR-Cas Development, Presented by Ann Marie B., Fida Biosystems ApS
P092: Rapid Sizing and Characterisation of Bispecific Antibodies, Presented by Ann Marie B., Fida Biosystems ApS
P093: Quantify and Characterize Any Protein Interaction – Even in Complex Backgrounds, Even with Challenging Targets, Presented by Gary R., Fluidic Analytics
P094: Discovery of Helical Peptide Therapeutics with Stapled Phage Display Screening, Presented by Olena T., FogPharma
P095: Evaluating the Versatility of Gator® Next Generation BLI Platform for Biotherapeutic Development and Gene Therapy, Presented by Harsha A., Gator Bio, Inc.
P096: Rapid and Easy Tool for Analyzing Viral and Lipid-Based Vectors Using BLI, Presented by Weijing G., Gator Bio, Inc.
P097: A Streamlined Data Analysis Workflow for Enhanced New Peak Detection (NPD) in the Multi-Attribute Method (MAM), Presented by Catherine E., Genedata AG
P098: Developing RNA Therapeutics with the Genedata Biopharma Platform, Presented by Jana H., Genedata AG
P099: A Streamlined Workflow for Analytical Characterization of Antibodies, Presented by Isabel K., Genedata AG
P100: Automating Assay Data Analysis Along the Discovery Pipeline, Presented by Isabel K., Genedata AG
P101: Yeast Surface Display of Full-Length IgG and Generation of Anti-Basigin Antibody, Presented by Youwei J., Genekine Biotech Co., Ltd.
P102: Systematic Pharmacological Analysis of Agonistic and Antagonistic Anti-FGFR1 MAbs Reveal a Similar Mechanism of Action, Presented by Joyce C., Genentech, Inc.
P103: Engineering PROTABs for Degradation of Cell Surface Receptors, Presented by Sheil K., Genentech, Inc.
P104: Don’t “FRET” Over It: Making (and Making Sense of) a Dually Conjugated DC-FRET Assay Detection Reagent, Presented by Justin L., Genentech, Inc.
P105: Mutually-Dependent IgG Antibody Combinations Engineered to Act Selectively on Cells Co-Expressing Two Antigens, Presented by Wilhem L., Genmab BV
P106: Characterizing Type III Kinase Inhibitor Using Laser-Free Flash Oxidation (Fox®) Hydroxyl Radical Protein Footprinting, Presented by Emily C., GenNext Technologies, Inc.
P107: Genovac Combines Multiple Species and Single B Cell Platforms to Increase Antibody Pool Diversity, Presented by Pete L., Genovac
P108: Effector Function Evaluation of Therapeutic Antibodies with Defined and Homogeneous Fc N-Glycans, Presented by Andrea P., Genovis AB
P109: Antibody Drug Development Solutions, Presented by Roumen B., GenScript
P110: Aura+: High Throughput, Low Volume Product Stability and Purity Analysis for Gene and Cell Therapies, Presented by Andrew S., Halo Labs
P111: Simultaneous Targeting of Primary Tumor, Draining Lymph Node, and Distant Metastases Through High Endothelial Venule-Targeted Delivery, Presented by Sungwook J., Harvard Medical School
P112: Immuno-Focusing a Leading Transmission-Blocking Vaccine Candidate by Epitope Masking Using Antigen Scaffolding and Glycan Engineering, Presented by Danton I., Hospital for Sick Children
P113: In Vitro Selection and Validation of Synthetic Single-Domain Antibodies and Applications, Presented by Brent P., Hybrigenics Services
P114: Incorporating Immobilized Enzymes in Tips on Liquid Handlers for Automated High-Throughput Glycomics and Proteomics Workflows, Presented by Dallas A., IMCS - Integrated Micro-Chromatography Systems, Inc.
P115: Incorporating Tip-Based Nucleic Acid Purifications on Liquid Handlers for Faster, Hands-Free Automation, Presented by Andrew L., IMCS - Integrated Micro-Chromatography Systems, Inc.
P116: Two Separate Chromatography Processes Using Tip-Based Protein Purifications on Liquid Handlers for Faster, Hands-Free Automation, Presented by Bill M., IMCS - Integrated Micro-Chromatography Systems, Inc.
P117: ImmTAAIs: TCR Targeted PD-1 Agonist Bispecifics for the Treatment of Autoimmune Diseases, Presented by David O., Immunocore Ltd.
P118: Targeting KRAS[G12D] Cancer Neoantigen with Soluble High Affinity T Cell Receptor Bispecific, Presented by Andrew P., Immunocore Ltd.
P119: IOS-1002-A Novel Multitarget Therapeutic Modulating 3 Checkpoint Pathways to Activate Both Adaptive and Innate Immunity, Presented by Anil K., ImmunOs Therapeutics AG
P120: Early Unwanted Immunogenicity Risk Assessment of Biotherapeutics, Presented by Chloe A., ImmunXperts, a Q² Solutions Company
P121: Functional Evaluation and Immunogenicity Assessment of Drug Candidates Using In Vitro Assays, Presented by Sofie P., ImmunXperts, a Q² Solutions Company
P122: In Vivo, Rapid Epitope and Paratope Mapping with Single Amino Acid Resolution, Presented by Faraz C., Immuto Scientific
P123: In-Vivo Structural Analysis and Epitope Mapping of Membrane Proteins In-Solution with Amino-Acid Resolution and High-Throughput, Presented by Hetal M., Immuto Scientific
P124: NMT Inhibitors as Novel Payloads for Antibody Drug Conjugates that Deliver Differentiated Activity, Presented by Josephine W., Imperial College London
P125: Isolation of Highly Selective Antibodies Against Claudin 18.2 and GPRC5D for Oncology Therapeutics, Presented by Ross C., Integral Molecular
P126: Characterization of SARS-COV-2 Antibodies Using Epitope Mapping and Pseudovirus Neutralization Assays, Presented by Ben D., Integral Molecular
P127: Screening the Membrane Proteome to Determine Antibody Specificity and De-Risk CAR-T Cell Development, Presented by Rachel F., Integral Molecular
P128: Development of CTIM-76, a Highly Specific Claudin 6 Bispecific Antibody for Treatment of Ovarian Cancer, Presented by Brad S., Integral Molecular
P129: Discovery of CCR8 Antibodies Targeting Regulatory T Cells to Enable Tumor Sensitization, Presented by Sharon W., Integral Molecular
P130: A Universal In Silico V(D)J Recombination Strategy for Developing Humanized Monoclonal Antibodies, Presented by Yuan-Chin H., I-Shou University
P131: Secondary Structure Estimation for Formulated Monoclonal Antibodies Using JASCO Spectra Manager 2.5 BeStSel CFR, Presented by Satoko S., JASCO Corporation
P132: Engineering Novel IgG Fc Glycosylation Sites for Bioconjugation, Presented by Zachary B., Johns Hopkins University
P133: Engineering Pan-Reactive VEGF Antagonists for Neovascular Eye Diseases, Presented by Paul S., Johns Hopkins University
P134: Hepassocin Acts to Ameliorate Inflammations and Liver Damage in Arthritis Model Mice, Presented by Mu-Shen C., Kaohsiung Medical University
P135: Developing a Pro-Immune Factor Antibody with a Spatial Hindrance Structure to Prevent Neutralization from Anti-Idiotypic Antibody and Enhance Therapeutic Efficacy, Presented by Yu-Tung C., Kaohsiung Medical University
P136: Targeting mPEGylated Liposome by One-Step Formulation with Bispecific Antibody to Enhance Therapeutic Efficacy in Hematologic Malignancies, Presented by Huei-Jen C., Kaohsiung Medical University
P137: Combining Methods of Clinical Protease Profiles and Automated Structure-Based Computational Simulation (MSCS 2.0) Enhances the Cleavability and Blocking Ability of the Disease-Activated Lock-Antibody, Presented by Tian-Lu C., Kaohsiung Medical University
P138: Developing a Universal Antibody Lock to Decrease the Immunogenicity of Antibody Drugs and Prolong the Pharmacokinetic of Pro-Antibody, Presented by Tzu-Yi L., Kaohsiung Medical University
P139: A Membrane-Tethered Chromogenic Enzyme System for Efficiently Monitoring Gene Expression, Presented by Wen-Wei L., Kaohsiung Medical University
P140: Development of a Bi-Specific Antibody (EphA2×mPEG) for Specific Targeting and Increase Endocytosis of Glycosidic Switch Liposomes to EphA2-Expressing Tumors, Presented by En-Shuo L., Kaohsiung Medical University
P141: Endogenous Anti-PEG Antibodies Reduce the Efficacy of COVID-19 mRNA Vaccine (BNT162b2), Presented by Yen-Ling L., Kaohsiung Medical University
P142: Characterization and Qualification of Adeno-Associated Virus Fill States Using Analytical Ultracentrifugation, Presented by Nikki M., KBI Biopharma
P143: Accelerated Development of Amber Codon Suppression Cell Line and a Bicistronic Vector Cell Line via Automated Gene Assembly System BioXP3250, Presented by Sharath M., Kemp Proteins
P144: Automated Viral Titer Methods Overestimate the Infectious Titer and Requires a Correction Factor Based on the Traditional IHC Assay, Presented by Grace V., Kemp Proteins
P145: Generation and Next Generation Sequencing-Based Characterization of a Large Human Combinatorial Antibody Library, Presented by Hye Lim C., Kookmin University
P146: Novel Bispecific Human Antibody Platform Specifically Targeting a Fully Open Spike Conformation Potently Neutralizes Multiple SARS-CoV-2 Variants, Presented by Ji Woong K., Kookmin University
P147: Development of Therapeutic Nonobodies Through Structural and Computational Design, Presented by Chandana S., Korea Research Institute of Bioscience and Biotechnology
P148: Unlocking the Full Potential of IgG Antibodies: Fc Variants Engineered for Enhanced Target Cell Clearance, Silenced Effector Function, or Prolonged Serum Persistence, Presented by Sang Taek J., Korea University
P149: A High-Throughput Platform for Targets Screening by Membrane Protein Library, Presented by Stephanie W., Kyinno Biotechnology
P150: A Machine Learning-Driven Approach for the Multiparametric Lead Optimisation of Anti-Tumour T-Cell Engagers, Presented by Michael M., LabGenius
P151: ALiCE- Simple Reaction Radical Results. Facile Scaling of Eukaryotic Cell-Free Protein Synthesis from Microliter to Liter Volumes with Consistent Yields, Presented by Andreas K., LenioBio GmbH
P152: Rapid Screening and Scaled Manufacture of Immunogenic Virus-Like Particles in a Tobacco BY-2 Cell Free Protein Synthesis System, Presented by Andreas K., LenioBio GmbH
P153: Singularity Mice: A Novel Genetic Platform for Developing Single Domain Antibodies and Multi-Specific Antibodies, Presented by Weisheng C., Leveragen
P154: Bottlenecks in Cell, Gene and mRNA Therapy: SUMO-Fusion to the Rescue, Presented by Abdul H., LifeSensors, Inc.
P155: Predictive Modeling of Concentration-Dependent Viscosity Behavior of Monoclonal Antibody Solutions Using Artificial Neural Networks, Presented by Christoph G., Lonza AG
P156: Satisfying Regulatory Requirements Using Orthogonal Methods for Glycosylation Analysis: An Example with a Monoclonal Antibody, Presented by Paulina U., Ludger Ltd.
P157: A Novel Universal Antibody-Based Adaptor Platform for Cancer Immunotherapy, Presented by Marlena S., Ludwig Maximilian University
P158: Cell Avidity Drives the Functional Responses of Immunotherapies with Superior Correlates to In Vivo Performance, Presented by Will S., LUMICKS
P159: Production of Fusion Bispecific Antibodies Using an Alternating Tangential Flow (ATF) Perfusion Culture System, Presented by Shaoyang Y., MabPlex
P160: STR: The First and Only Truly Silent Fc Technology, Presented by Ian W., mAbsolve
P161: Illuminating the Cellular Uptake of HaloTag and Its Localization via a pH-Sensitive Fluorophore, Presented by JoLynn G., Massachusetts Institute of Technology
P162: Site-Specific Antibody Conjugation Through Bisected N-Glycans with the Preserved Glycoengineering Capability, Presented by Yen-Pang H., Merck & Co., Inc.
P163: Automated Protein Normalization: Enhanced Efficiency and Reproducibility Using Lynx VVP Technology, Presented by Catherine R., Merck & Co., Inc.
P164: Fully Automated, HT Protein Production from Transient ExpiCHO Expressions: Method Development and Optimization, Presented by Kendal W., Merck & Co., Inc.
P165: Discovery and Engineering of Potent Notch Modulators, Presented by Elliot M., Moffitt Cancer Center
P166: Protein Engineering Reveals Structural Insights into LAG3 Immunosuppressive Function, Presented by Qianqian M., Moffitt Cancer Center
P167: Bispecific Nanobodies for Detection of Axillary Lymph Node Metastases in Breast Cancer, Presented by Srishti S., Moffitt Cancer Center
P168: Mesothelin-Targeting Bispecific T Cell Engagers that Retain Anticancer Activity upon Exposure to Shed Mesothelin, Presented by Anirban C., National Institutes of Health, National Cancer Institute
P169: Dromedary Camel Nanobodies Neutralize SARS-CoV-2 Variants, Presented by Jessica H., National Institutes of Health, National Cancer Institute
P170: Camel Nanobody-Based B7-H3 CAR-T Cells with High Efficacy Against Large Solid Tumors, Presented by Dan L., National Institutes of Health, National Cancer Institute
P171: Engineering T Cells Targeting GPC2 for Treating Neuroblastoma, Presented by Alex Q., National Institutes of Health, National Cancer Institute
P172: Identification and Structural Analyses of Highly Protective Anti-Malarial Antibodies, Presented by Prabhanshu T., National Institutes of Health, National Institute of Allergy and Infectious Diseases
P173: Structure-Guided Engineering of a High-Affinity Anti-Methoxy Poly(ethylene Glycol) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics, Presented by Yu-Cheng S., National Yang Ming Chiao Tung University
P174: An E. coli Cell Lysate Based System for In Vitro Protein Synthesis, Presented by Paula M., New England Biolabs, Inc.
P175: A Broad-Specificity O-Glycoprotease Enables Improved Analysis of Glycoproteins and Glycopeptides Containing Intact Complex O-Glycans, Presented by Saulius V., New England Biolabs, Inc.
P176: Discovery of Potent and Functional Fully Human Antibodies Against CD36 for Cancer Immunotherapy, Presented by Musheng B., Nona Biosciences
P177: HBM9014 Is a Fully Human Anti-LIFR Antibody with Excellent Preclinical Efficacy and Safety Profile, Presented by Joe Z., Nona Biosciences
P178: The Silicon Germinal Center® (SGC): Screening Recombinant Antibodies in Mammalian cells with Reversible Membrane Display, Presented by Scott D., OCMS Bio
P179: Discovery of High Affinity Antibodies Against a GPCR Target by mRNA Immunization of OmniChicken®, Presented by Vivian H., OmniAb, Inc.
P180: PSCA Expressions in Cancers: A Potential Prognostic Marker and Target for Immunotherapy, Presented by Yichen G., OriGene Technologies, Inc.
P181: FcyRIIa-Specific DARPins as Novel Tools in Blood Cell Analysis and Platelet Clotting, Presented by Samuel T., Paul Ehrlich Institut
P182: Application of LabChip Empty/Full Microfluidic Assays for AAV2 and AAV9 Analysis, Presented by Dipti M., PerkinElmer
P183: Measurement of AAV Protein Composition and Empty/Full Analysis Using Microfluidics, Presented by James W., PerkinElmer
P184: High-Throughput Cell-Free In Vitro Protein Expression, Purification, and Functional Evaluation on Beacon Optofluidic System, Presented by Or G., PhenomeX
P185: Multi-Omic Analysis for Directly Linking T Cell Phenotype to Gene Expression, Presented by Or G., PhenomeX
P186: Lenti.RiGHT – Epigenetic Targeting Delivers Cutting-Edge Lentivirus Producer Cell Lines, Presented by Volker S., ProBioGen AG
P187: Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T Cell Redirecting Therapy, Presented by Mei C., Promega Corporation
P188: Development of Bioluminescent No-Wash Fc Gamma Receptor Binding Immunoassay to Guide the Development of Antibody Therapeutics, Presented by Kai H., Promega Corporation
P189: Cell-Based Luminescent Reporter Bioassays for Immunotherapies Targeting Macrophage Effector Functions, Presented by Lennart B., Promega Corporation
P190: Novel icIEF-Based Fractionation of Therapeutic Antibody Charge Variant for LC-MS Characterization, Presented by Jessica D., ProteinSimple, a Bio-Techne Brand
P191: Rapid Purity and Charge Heterogeneity Analysis of Anti-CD4 mAb Culture Variants by Maurice™, Presented by Yasef K., ProteinSimple, a Bio-Techne brand
P192: Development of Gemtuzumab-Targeted Dual-Drug Loaded Nanoparticles for the Treatment of Paediatric Acute Myeloid Leukaemia, Presented by Ana C., Queen's University Belfast
P193: Engineering Anti-Malarial Antibody with High Affinity by Reiteration of Site Saturation Mutagenesis and High-Throughput Screening, Presented by Jihwan C., Ragon Institute of Mass General, MIT, and Harvard
P194: Enhanced Antibody Recognition Against HIV Resistant Strains by Directed Evolution, Presented by Matheus O., Ragon Institute of Mass General, MIT, and Harvard
P195: Immortalization and Functional Analyses of Human Natively Paired Antibody Repertoires from HIV-1 Chronically Infected Patients, Presented by Xiaoli P., Ragon Institute of Mass General, MIT, and Harvard
P196: Exploring the Potential of Antibody Discovery Through Proteomics and De Novo Sequencing of Polyclonal Antibodies: An Alpaca Case Study, Presented by Anthony S., Rapid Novor
P197: Structure, Stability, Similarity, and Stress Characterization of Trastuzumab and Two Biosimilar Drugs Using Microfluidic Modulation Spectroscopy (MMS), Presented by David S., RedShift Bio
P198: Measuring Protein-Protein Interactions with Mass Photometry, Presented by Kate S., Refeyn, Inc.
P199: Multidomain Peptide Hydrogels as Scaffolds for T-Cell Applications, Presented by Viridiana LA., Rice University
P200: Engineering of DutaFabs, Presented by Davide B., Roche Diagnostics GmbH
P201: Modeling NGS Data from Display Campaigns with Gaussian Processes, Presented by Wing Ki W., Roche Diagnostics GmbH
P202: Development of Anti-Host Cell Protein Antibodies and Reagent Qualification using Orthogonal Analytical Methods, Presented by Dan K., Rockland Immunochemicals, Inc.
P203: Discovery of Novel Therapeutics Against GPCRs, Ion Channels and Transporters with the Salipro Platform, Presented by Sara B., Salipro Biotech AB
P204: DEVELOPICK™: Samsung Biologics Developability Assessment Platform - A Rapid and Accurate Evaluation Tool for Molecular Stability, Presented by Seahee K., Samsung Biologics
P205: Increasing Productivity in Biologics Development by Using Octet® Bio-Layer Interferometry Platforms, Presented by Nilshad S., Sartorius
P206: Simplifying Data Compliance for Multi-Channel Capillary Electrophoresis, Presented by Philip H., SCIEX
P207: Single-Cell Interactive Cytometry Using Made-to-Order Droplet Ensembles, Presented by Russell C., Scribe Biosciences
P208: Prophylactic Epstein Barr Virus Vaccine Design with Engineered Prefusion Stabilized gB Variants, Presented by Bianka H., Seattle Children's Research Institute
P209: ROR1 VHH Therapeutic Design, Presented by Jason P., Seattle Children's Research Institute
P210: Augmenting Ex Vivo T Cell Activation and Expansion with Soluble Circular Tandem Repeat Protein Scaffolded Agonists, Presented by Raymond R., Seattle Children's Research Institute
P211: Identifying Ig Selective Proteases for Treatment of Autoimmune Disease Using the IMPACT Platforms, Presented by June S., Seismic Therapeutic
P212: Development and Deimmunization of Protein Therapeutics by Machine Learning, Presented by Nathan R., Seismic Therapeutic
P213: Discovery and Characterization of FcgRIIb Specific mAbs, Presented by Elliott W., Seismic Therapeutic
P214: H-map: Amino Acid Generator for Designing and Scoring Protein Binders Without Backbone Structure Information, Presented by Hyeonuk W., Seoul National University
P215: BA1302, a Novel, Investigational CD228-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors, Presented by Shuo W., Shandong Boan Biotechnology Co. Ltd.
P216: A Novel ROR1/CD3 Bispecific TCE with Excellent ROR1 Specific Killing Effect, Presented by Jinghua G., Shanghai Taijin Biotechnology Co., Ltd.
P217: Molecular Guidance Systems (MGS) as a Versatile Vehicle for Cell-Specific Targeted Delivery of Nucleic Acid Therapeutics, Presented by Michael M., SRI International
P218: Going Beyond the Blood-Brain Barrier: Delivery of Diverse Cargo to Targeted Cells Within the Central Nervous System, Presented by Amanda P., SRI International
P219: Expanding Cancer Immunotherapy by Exploiting Recall Immunity – A New Co-Therapy Option for Checkpoint Inhibitors, Presented by Indu V., SRI International
P220: Targeting Treg Cells by TNFR2 Antibody Induces Tumor Regression In Vivo, Presented by Wenwu Z., Staidson Biopharma, Inc.
P221: EcCustom: A Platform for Customizing E. coli for Recombinant Protein Production, Presented by Alexandros K., Stockholm University
P222: CRBN Is Downregulated in Lung Cancer and Negatively Regulates TLR2,4 and 7 Stimulation in Lung Cancer Cells, Presented by Mi-Jeong K., Sungkyunkwan University
P223: Stratifin (SFN) Regulates Lung Cancer Progression via Nucleating the Vps34-BECN1-TRAF6 Complex for Autophagy Induction, Presented by Jiyoung K., Sungkyunkwan University
P224: Discovery of STRO-003, a Novel ROR1 Targeting ADC Using Cell Free Protein Synthesis and Site-Specific Conjugation Technologies, Presented by Garrett G., Sutro Biopharma, Inc.
P225: Half-Life Extended Engineered IL18 Variants that Escape the Negative Regulation of IL18BP, Presented by Eunice K., Sutro Biopharma, Inc.
P226: Development of an iLite® Reporter Cell Platform for the Quantification of Anti-AAV Neutralizing Antibodies, Presented by Jordi RM., Svar Life Science
P227: Functional Bioassays Measuring the Potency of Complement Therapeutics, Presented by Therese S., Svar Life Science
P228: Quantification of Bispecific Antibody-Mediated T-Cell Activation with Engineered CD3 Effector and Tailored Target Cells, Presented by Therese S., Svar Life Science
P229: First-in-Class Non-Genetic Generation of DAR1 Antibody-Conjugates for Application with Ultra-Potent Payloads and Immune Cell Engagers, Presented by Sander V., Synaffix
P230: Preclinical Assessment of GlycoConnect™ ADCs with Potency-Modulated Analogues of PNU-159,682, Presented by Floris V., Synaffix
P231: Optimized Receptor Design to Improve CAR-T Cell Efficacy, Presented by Maeta S., Sysmex Corporation
P232: Rapid Production of EGFR-Specific Armed T Cells Using a Non-Genetic Engineering Platform, Presented by Michael C., Taipei Medical University
P233: Development of Antagonistic BACE-2 Antibodies to Improve Type 2 Diabetes by Inducing Pancreatic Beta-Cells Proliferation, Presented by Kuo-Hsiang C., Taipei Medical University
P234: Dual Blockade of HSP90/HDAC6 Effectively Destroys the Immunosuppressive Tumor Microenvironment and Prevents Tumor Recurrence, Presented by Tung Yun W., Taipei Medical University
P235: Identification of Bioanalytical Antibodies Using Digital SPR, Presented by Brian W., Nicoya
P236: Development of a NanoString-Based High-Throughput miRNA Detection Workflow for Mouse Whole Blood and Serum Samples, Presented by Josephine F., Takeda Pharmaceutical Co. Ltd.
P237: Identification of Binning Diversity and Binding Properties of SARS-CoV-2 Antibodies Using Carterra LSA, Presented by Hazal K., Takeda Pharmaceutical Co. Ltd.
P238: High Throughput CAR Cell Production and Characterization with Repeat Antigen Stimulation Assay, Presented by Sophie M., Takeda Pharmaceutical Co. Ltd.
P239: High Throughput Multiplex Protein and Cell Based Binding Assay Development for Phage Display Antibody Discovery, Presented by Nicholas T., Takeda Pharmaceutical Co. Ltd.
P240: Discover Potent and Selective Antibodies Using a Yeast Display Platform, Presented by Weihong Y., Takeda Pharmaceutical Co. Ltd.
P241: Multi-Specific c:Met x EGFR x VEGF Antibody for Difficult to Treat Cancers, Presented by Mark T., Tavotek
P242: TavoSelect Process Generates Multiple Diverse Single Domain Epitope Bins, Presented by Mark T., Tavotek
P243: In Vivo Detoxification of Amatoxin-Based ADCs (ATACs®) by “Click” Chemistry, Presented by Alessandra T., Technical University of Munich
P244: Rational Crystal Contact Engineering as a Tool for Enhancing Preparative Protein Crystallization, Presented by Brigitte W., Technical University of Munich
P245: Sequence In, mRNA Out. A New Paradigm to Accelerate Discovery of mRNA Vaccines and Therapeutics, Presented by Ankita D., Telesis
P246: Flow Cytometry: Applications and Considerations in Analytical Methods Development and Qualification, Presented by Huan C., Teva Pharmaceuticals
P247: Site-Specific Conjugation of Novel Fluorophores, Molecular Imaging Reagents, and ADC Toxins to Streamline Immunotherapy Discovery and Development, Presented by Brian A., Thermo Fisher Scientific
P248: Accelerating Discovery and Rational Design of Biologics with Cryo-EM, Presented by Pascal L., Thermo Fisher Scientific
P249: Setting Up an Effective Protein Expression Workflow, Presented by Matt M., Thermo Fisher Scientific
P250: High-Throughput Protein Production Enables Rapid Identification of Variants Exhibiting Desired Characteristics, Presented by Zachary S., Tierra Biosciences
P251: Modeling Anti-Cancer Therapies in Advanced Human Immune System Mouse Models, Presented by Kiave H., TransCure bioServices
P252: Discovery of Functional Anti-DKK1 Antibodies with an Integrated Platform, Presented by Zhen H., Twist Bioscience
P253: Leveraging Twist’s Library of Libraries for The Identification and Functional Antibody Validation for LAG-3 Immunotherapy, Presented by Wes S., Twist Bioscience
P254: Pyridazinediones, a Modular Platform for the Development of Next-Generation Protein Conjugates: From Chemical Construction of Bispecifics and Tuneable Payload Conjugates to Reversible Cysteine Modification, Presented by Lea R., University College London
P255: CAR T Cells Are Effective at Treating Aggressive Fungal Infections, Presented by Michelle S., University Hospital Wuerzburg
P256: Long-Lasting Expression of Transgenes in Mouse Primary Fibroblast-Like Synoviocytes with Self-Amplifying RNA, Presented by Tony L., University of Cambridge
P257: Affinity Maturation of Computationally Designed Fragment for Next-Generation Nanobody Discovery, Presented by Xing X., University of Cambridge
P258: Single Molecule FRET Reveals Protein Dual Stabilization Mechanism in an Immobilization Support, Presented by Hector SM., University of Colorado, Boulder
P259: Rabbit Derived VL Single-Domain Antibodies Scaffolds and In Vivo Phage Display Selections as a Promising Platform to Develop Highly Specific and Potent Antibody-Drug Conjugated Compounds, Presented by Frederico A., University of Lisbon
P260: ITGA4 Knockout Prevents Blood-Brain-Barrier Migration of CAR T Cells, Presented by Kenneth D., University of Maryland, Baltimore
P261: A Novel Interpretable Machine Learning Method Enables Prediction of Continuous Properties and Accelerates Protein Engineering Tasks from Directed Evolution Experiments, Presented by Marshall C., University of Michigan
P262: A Mechanistic Study of Enhertu and Kadcyla Reveals the Importance of Matching Payload Delivery with its Potency, Presented by Shujun D., University of Michigan
P263: High Avidity, Low Affinity Antibody Optimizes Antibody Drug Conjugate Tissue Penetration at Multiple Expression Levels, Presented by Anna K., University of Michigan
P264: Development of HER2+ Syngeneic Model for Understanding ADC in Clinical Success, Presented by Hyeyoung K., University of Michigan
P265: Synthetic Mini-Protein Scaffolds to Engineer Developable Ligands for Immune Modulation and Insulin Receptor Antagonism, Presented by Paul B., University of Minnesota
P266: Characterizing Antibody Internalization for Rational Selection of ADC Linker Design, Presented by Zekun S., University of Minnesota
P267: Controlled Fab-Arm Exchange on mAb² Pairs for the Production of Multipecific Antibodies, Presented by Veronica N., University of Natural Resources and Life Sciences
P268: Bispecific Antibodies for Allergy Treatment, Presented by Aleksandra R., University of Natural Resources and Life Sciences
P269: Decoding Amyloidosis in Human Antibody Light Chains, Presented by Puneet R., University of Oslo
P270: Elastin-Like Polypeptides (ELPs) for the Delivery of αB Crystallin Peptide to the Retinal Pigment Epithelial Cells, Presented by Sara A., University of Southern California
P271: Multicomponent Reaction for the Site-Selective Conjugation of Monoclonal Antibodies, Presented by Ilias K., University of Strasbourg
P272: A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Potent Antibody-Drug Conjugates, Presented by Lorenzo T., University of Strasbourg
P273: Antibodies Neutralizing the Adenylate Cyclase Toxin Synergize with Anti-Pertactin Antibodies to Protect Mice Against B. pertussis, Presented by Dzifa A., University of Texas at Austin
P274: Generation of Highly Selective Monoclonal Antibodies Inhibiting Matrix Metalloproteinases by Periplasmic Genetic Selection, Presented by Ki Baek L., University of Texas at Houston
P275: High-Fidelity Large-Diversity Monoclonal Mammalian Cell Libraries by Cell Cycle Arrested RMCE, Presented by Zening W., University of Texas at Houston
P276: Functional Delineation of a Protein–Membrane Interaction Hotspot Site on the HIV-1 Neutralizing Antibody 10E8, Presented by Sara IG., University of the Basque Country
P277: Development of Novel Biotherapeutic Agents for Tumor-Specific Delivery of Cytotoxic Agents, Presented by Izaskun M., University of the Basque Country
P278: Development of Nanobodies Based Chimeras as Synthetic Calibrators for Immunodiagnosis, Presented by Gabriel L., University of Uruguay
P279: A Variable Lymphocyte Receptor Capable of Delivering Therapeutics to Glioblastoma, Presented by Elizabeth A., University of Wisconsin, Madison
P280: Native Complex Membrane Antigen Expression on Poxvirus for Antibody Discovery, Presented by Maria S., Vaccinex
P281: Increased Productivity with Rapid CIP Using GORE Protein Capture Devices with Protein A and Demonstrated Scalability, Presented by Lauren P., W. L. Gore & Associates, Inc.
P282: Novel Tyrosine Click Chemistry Platform to Access Bispecific T-Cell Engagers, Presented by Irene S., Wageningen University and Research
P283: Improving Analysis of Quality Indicating Attributes for Better Lifecycle Management, Presented by Robert B., Waters Corporation
P284: Overcoming the Challenges in Asymmetric Bispecific Antibody Production by Using Quick’n Clean Platform, Presented by Mark C., WuXi Biologics
P285: Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers, Presented by Siwei N., WuXi Biologics
P286: Overcoming Technical Challenges with BsAbs and MsAbs Using Novel Technology Platforms, Presented by Siwei N., WuXi Biologics
P287: Integrated Analytical Platform to Support Biologic Drug Discovery and Beyond, Presented by Yongsheng X., WuXi Biologics
P288: Tumor-Specific CD28 Costimulatory XmAb Bispecific Antibodies Enhance T Cell Activation in Solid Tumors, Presented by Matthew F., Xencor, Inc.
P289: Fully AI-Driven Humanoid VHH Phage Library, Presented by Yunfei L., XtalPi, Inc.
P290: TriTCE Co-Stim, Next Generation Costimulatory Trispecific T Cell Engagers for the Treatment of Solid Tumors, Presented by Purva B., Zymeworks, Inc.
P291: Optimization of Purine-Based TLR7 Agonists as Payloads for Immune-Stimulating Antibody Conjugates (ISACs), Presented by Graham G., Zymeworks, Inc.
P292: Alco5 – Technology-Enabled Payload Solutions to Broaden the Scope of Conjugatable Drugs, Presented by Jonas HS., Tubulis GmbH
P293: Development of a Drug Discovery Platform with Phage Displayed Cystine Knot Peptide Scaffolds and Discovery of Potent and Stable Peptide Antagonists Against VEGF, Presented by Lijuan Z., Genentech, Inc.
P294: Pelican Expression Technology® - A Versatile and Robust Protein Expression Platform for the Development of Next Generation Protein Therapeutics, Presented by Adam C., Ligand Pharmaceuticals
P295: SARS-CoV-2 Neutralizing Antibodies Discovered Across Three Individuals Following Vaccination and Infection Show Diverse Epitopes Across Virus Spike Protein, Presented by Thiago L., Abterra Biosciences
P296: Long-Term Virologic Suppression Following AAV Delivery of Anti-HIV Monoclonal Antibodies, Presented by Jose MN., University of Miami
P297: A Faster and Sensitive CHO HCP Impurity Quantification Workflow - AlphaLISA® & HTRF® CHO Host Cell Protein Kits, Presented by Jordan A., PerkinElmer
P298: AlphaLISA Adeno Associated Virus (AAV) Kits – A Faster and More Sensitive AAV Capsid Detection Method, Presented by Daniel C., PerkinElmer
P299: Cell Identity, Count, and Viability for Critical Quality Attributes Using the Cellaca® PLX Image Cytometer, Presented by Pragnesh P., PerkinElmer
P300: Rapid No Wash Assays for Characterizing a Mouse TIGIT/PD-L1 Bispecific Antibody, Presented by Jerry P., PerkinElmer
P301: Development of an Immunomodulatory AAV Viral Vector to Minimizing Adaptive Immune Responses to AAV-Delivered Broadly Neutralizing Antibodies, Presented by James T., University of Miami